JAK2 inactivating mutations promotes endometrial cancer progression by targeting HIF-1α
These findings revealed novel molecular mechanisms underlying JAK2 LOF mutations-driven endometrial tumorigenesis and revealed that the HIF-1α pathway may be a potential therapeutic target in JAK2-mutated endometrial cancer.
Authors
- Weijian Zeng
- Xuan Zheng (ORCID: https://orcid.org/0000-0001-6283-8165)
- Juan Wang (ORCID: https://orcid.org/0000-0003-1305-190X)
- Zheng Chen (ORCID: https://orcid.org/0000-0002-6367-7647)
- Qin Lin (ORCID: https://orcid.org/0000-0002-5703-9112)
Institutions
- Shanghai Jiao Tong University (CN)
- International Peace Maternity & Child Health Hospital (CN)
- Hangzhou DAC Biotech (China) (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1007/s12672-024-01722-6
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China